Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 8-K (Current Report)
Report Date: February 25, 2026
Reporting Period: Fourth quarter and fiscal year ended December 31, 2025
This filing serves as a notification that the Company issued a press release and an earnings presentation regarding its financial results for the period ended December 31, 2025. The detailed financial data is contained in the attached exhibits (Exhibit 99.1 and 99.2) and is not embedded directly within the text of this Form 8-K.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the press release (Exhibit 99.1) and the earnings presentation (Exhibit 99.2) attached to the filing.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. Investors must refer to the incorporated press release and presentation for comparative analysis.
Guidance, Outlook, and Risks
Management Commentary: The Company released a presentation in connection with its earnings call on February 25, 2026, which likely contains management commentary and outlook, though the specific content is not detailed in this summary text.
Disclosure Channels: The Company utilizes SEC filings, its investor relations website (https://ir.recursion.com/), press releases, conference calls, and social media to communicate material information.
Legal Status of Information: Information furnished under Item 2.02 and Item 7.01 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2025 financial results.
- Review Exhibit 99.2 (Earnings Presentation) for management guidance, strategic outlook, and operational updates.
- Verify the Company's cash position and burn rate, as these are critical for a biopharmaceutical entity not reporting revenue figures in this summary.
- Monitor the investor relations website for any subsequent updates or clarifications regarding the February 25, 2026, announcement.